• Jennifer M Watkins, Mazen M Dimachkie, Patty Riley, and Elyse Murphy.
• Questions or comments about this article may be directed to Jennifer M. Watkins, MSN APRN AGAC-NP, at watkins.jenni@gmail.com. She is a Nurse Practitioner, Neuromuscular Medicine, University of Kansas Medical Center, Kansas City, KS. Mazen M. Dimachkie, MD FAAN FANA, is Professor of Neurology and Director of the Neuromuscular Division, University of Kansas Medical Center, Kansas City, KS. Patty Riley, RN BAN CRNI, is Executive Medical Science Liaison, Immunoglobulins, Medical Affairs, CSL Behring, King of Prussia, PA. Elyse Murphy, BSN RN, is Associate Director, Medical Field Team, Immunoglobulins, Medical Affairs, CSL Behring, King of Prussia, PA.
• J Neurosci Nurs. 2019 Aug 1; 51 (4): 198-203.

AbstractChronic inflammatory demyelinating polyneuropathy (CIDP), an immune-mediated peripheral neuropathy, is frequently treated with long-term maintenance intravenous immunoglobulin (IVIG). However, disadvantages of IVIG are the systemic adverse reactions, lengthy infusions, and need for vascular access. Subcutaneous immunoglobulin (SCIG) addresses many of the issues encountered by those unable, or unwilling, to tolerate the treatment burden of long-term IVIG. Subcutaneous immunoglobulin, a 20% solution stabilized with L-proline, is US Food and Drug Administration-approved for CIDP maintenance therapy in patients after being stabilized with IVIG. Approval was based on a randomized, double-blind, placebo-controlled trial where SCIG demonstrated superiority over placebo and was safe and efficacious in maintaining function. In addition to reviewing the primary efficacy results from the clinical trial, this article aims to update the neurology nursing community on a new option for long-term management of CIDP, including the practicalities of initiating and maintaining patients on SCIG therapy.

12 keywords...

hide…